Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

manilatimes.net · 2026-10-24

Media Release

TickrTrends take: Incyte's collaboration with Genmab to advance a clinical trial in metastatic colorectal cancer represents a pipeline expansion in oncology, an area central to its revenue growth trajectory. TickrTrends currently assesses INCY as undervalued within the Healthcare sector, making clinical progress in late-stage development particularly relevant to investors monitoring the company's future earnings potential. The success or advancement of this partnership could materially influence the company's long-term competitive position and asset value relative to current market pricing.

Read the full story at manilatimes.net →